Compare CFFN & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | NTLA |
|---|---|---|
| Founded | 1893 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 905.3M | 986.9M |
| IPO Year | 1999 | 2016 |
| Metric | CFFN | NTLA |
|---|---|---|
| Price | $6.75 | $14.67 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 19 |
| Target Price | $6.75 | ★ $17.32 |
| AVG Volume (30 Days) | 885.5K | ★ 5.4M |
| Earning Date | 01-28-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | ★ 79.31 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $200,291,000.00 | $57,528,000.00 |
| Revenue This Year | $16.44 | $1.96 |
| Revenue Next Year | $3.40 | N/A |
| P/E Ratio | $13.40 | ★ N/A |
| Revenue Growth | 20.62 | ★ 33.52 |
| 52 Week Low | $4.90 | $5.90 |
| 52 Week High | $7.31 | $28.25 |
| Indicator | CFFN | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 72.71 |
| Support Level | $6.61 | $11.34 |
| Resistance Level | $7.13 | $9.62 |
| Average True Range (ATR) | 0.17 | 1.08 |
| MACD | 0.00 | 0.53 |
| Stochastic Oscillator | 36.36 | 81.16 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.